肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions.
Richter转化（RT）是慢性淋巴细胞白血病（CLL）向更具侵袭性的淋巴瘤（通常为弥漫大B细胞淋巴瘤（DLBCL））演变的一种危及生命的进展，标志着CLL管理中的一个艰难节点，因为其预后差且治疗选择有限。
Richter转化（RT）是慢性淋巴细胞白血病（CLL）向更具侵袭性的淋巴瘤——通常为弥漫大B细胞淋巴瘤（DLBCL）——演变的一种危及生命的进展，由于预后差且治疗选择有限，标志着CLL管理中的一个艰难节点。本综述深入探讨了RT当前的治疗格局。尽管传统化学免疫治疗（CIT）方案如R-CHOP及其变体的疗效有限，该方案仍是最常推荐的标准治疗。多种治疗策略正在研究中，包括靶向激酶抑制剂、检查点抑制剂、双特异性抗体和CAR T疗法。鉴于RT的复杂性质以及不断演变的治疗范式，持续的研究对于优化治疗策略和整合新型治疗药物以改善RT患者的生存和生活质量至关重要。鉴于RT管理中缺乏明确的标准方法，在可行的情况下应优先让RT患者参加临床试验。
Richter's transformation (RT) is a life-threatening evolution of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL), marking a challenging juncture in CLL management due to the associated poor prognosis and limited treatment options. This review delves into the current therapeutic landscape for RT. Despite the modest efficacy of traditional chemoimmunotherapy (CIT) regimens such as R-CHOP and its variations, this regimen remains the most commonly recommended standard of care. Multiple therapeutic strategies are under investigation, including targeted kinase inhibitors, checkpoint inhibitors, bispecific antibodies, and CAR T therapy. Given the complex nature of RT and the evolving therapeutic paradigms, ongoing research is imperative to refine treatment strategies and integrate novel therapeutic agents to enhance survival and quality of life for people with RT. Given the lack of a clear standard of approach in the management of RT, patients with RT should be prioritized to enroll on clinical trials where feasible.
MEMBER ACCOUNT
登录成功会直接打开下一页。
